TICKERNERD
Menu
SGPHealthcare · Biotechnology

SGP Stock Forecast: SpyGlass Pharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$26
+0.69% on the day

The 6 Wall Street analysts covering SpyGlass Pharma, Inc. hold a median 12-month price target of $42 — +59.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$886.7M
Ticker Nerd rank
1 / 100
Median analyst target
$42
Analysts covering
6
Total return, dividends reinvested
1W
+0.8%
1M
+30.3%
From high
−11.0%
From low
+50.4%
$18
$30
Range since 6 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SGP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SpyGlass Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
47
Revisions
31
Momentum
22
Issuance
12
Growth
8
Accruals
8
Value
5
Volatility
4
Quality
2

Size (47): Smaller than most of the companies we track.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Feb 2026Adjusted close, US dollars
$20$30$40$50$60Mar 26Apr 26May 26Jun 26Jul 26Aug 26SGPHigh $62Median $42Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $37Median $42High $62

The green dot is the last close — the median target sits +59.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Raymond JamesInitiatesOutperform$39
10 Mar 2026HC Wainwright & Co.InitiatesBuy—
10 Mar 2026HC Wainwright & Co.InitiatesBuy$37
3 Mar 2026CitigroupInitiatesBuy—
3 Mar 2026CitigroupInitiatesBuy$42
3 Mar 2026JefferiesInitiatesBuy—
3 Mar 2026JefferiesInitiatesBuy$62
3 Mar 2026Leerink PartnersInitiatesOutperform—
3 Mar 2026Leerink PartnersInitiatesOutperform$42
3 Mar 2026StifelInitiatesBuy$42
3 Mar 2026StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SGP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

SpyGlass Pharma, Inc. (SGP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.1×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
3.5×

Cheaper than 30% of US stocks

EV / EBITDA
−10.7×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
40.3%

Higher than 91% of US stocks

Return on assets
−34.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SGP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGPSpyGlass Pharma, Inc.$886.7M
1
FDMT4D Molecular Therapeutics, Inc.$874.5M
53
TBPHTheravance Biopharma, Inc.$856.6M
89
RIGLRigel Pharmaceuticals, Inc.$849.1M
79
DSGNDesign Therapeutics, Inc.$924.5M
66
OLMAOlema Pharmaceuticals, Inc.$931.7M
29
ACRSAclaris Therapeutics, Inc.$943.5M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SpyGlass Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGP news & analysis

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 6 Aug 2026positive

SpyGlass Pharma reported its second quarter 2026 financial results and provided corporate updates. Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System, with completion expected in 2027, and the Bimatoprost Drug Ring System first-in-human trial is on track to start in the second half of 2026.

Why it matters — SGP watchers would care because the company confirmed its key clinical programs remain on schedule, with the Phase 3 BIM-IOL System trial projected to complete enrollment in 2027 and the BIM-DRS first-in-human trial slated to begin in late 2026.

FAQ

Frequently asked questions about SGP stock

What is the SGP stock price forecast for 2026-2027?

The 6 Wall Street analysts covering SpyGlass Pharma, Inc. have a median 12-month price target of $42, with estimates ranging from $37 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGP stock a buy right now?

Of the 6 analysts covering SpyGlass Pharma, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SpyGlass Pharma, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGP?

As at 22 Aug 2026, SpyGlass Pharma, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (47 of 100).

Will SGP stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +59.0% from the last close, and Ticker Nerd's factor model ranks SpyGlass Pharma, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGP stock forecast for 2030?

No analyst covering SpyGlass Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $62 over the next 12 months.

What does SpyGlass Pharma, Inc. do?

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company specializing in sustained drug delivery solutions for chronic eye conditions, particularly open-angle glaucoma and ocular hypertension.

What is the latest news on SGP?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates". SpyGlass Pharma reported its second quarter 2026 financial results and provided corporate updates. Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System, with completion expected in 2027, and the Bimatoprost Drug Ring System first-in-human trial is on track to start in the second half of 2026.

Company

About SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company specializing in sustained drug delivery solutions for chronic eye conditions, particularly open-angle glaucoma and ocular hypertension. Founded in 2019 by Malik Y. Kahook, M.D., and Glenn Sussman, the company develops innovative platforms that integrate approved medicines like bimatoprost into familiar surgical procedures to provide long-term disease control and vision preservation. Its lead candidate, the BIM-IOL System, combines proprietary drug pads with intraocular lenses for implantation during routine cataract surgery, delivering therapy over three years and addressing treatment gaps in daily eye drops. Additionally, the BIM-DRS targets glaucoma patients not undergoing cataract surgery. Headquartered in Aliso Viejo, California, SpyGlass Pharma employs 65 professionals and is led by CEO Patrick Mooney, with a team boasting deep expertise in ophthalmology, drug delivery, and clinical development. The company's non-bioerodible SpyGlass Platform originated from the University of Colorado Anschutz School of Medicine, positioning it to transform ophthalmic care by reducing patient burden and enhancing outcomes in the healthcare sector.

CEO Mr. Patrick H. Mooney · 76 employees · United States · https://www.spyglasspharma.com